Serum potassium abnormalities, renin-angiotensin-aldosterone system inhibitor discontinuation, and clinical outcomes in patients with chronic cardiovascular, metabolic, and renal conditions: A population-based analysis
European Journal of Internal Medicine · 2024
DOI: 10.1016/j.ejim.2024.03.021 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift European Journal of Internal Medicine, 2024. Verfasst von Santiago Jiménez-Marrero und 15 weiteren Autor:innen. Beteiligte Einrichtung: Bioheart Group, Cardiovascular, Respiratory and Systemic Diseases and cellular aging Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL…. Hauptthemen laut MEDLINE: Hyperkalemia, Angiotensin-Converting Enzyme Inhibitors, Renin-Angiotensin System, Potassium. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: CSL Vifor.
Abstract (Originalsprache)
BACKGROUND: Renin-angiotensin-aldosterone system inhibitors (RAASIs) play a crucial role in the treatment of several chronic cardiovascular conditions. Nonetheless, hyperkalemia, a frequent side effect, often leads to the discontinuation of RAASIs. The implications of hyperkalemia-driven changes in RAASI medications are poorly understood. METHODS: Population-based, observational, retrospective cohort study. Two large healthcare databases were utilized to identify 77,089 individuals aged 55 years and older with chronic conditions who were prescribed RAASIs between 2015 and 2017 in Southern Barcelona, Spain. We assessed the interplay between serum potassium abnormalities, RAASI management, and their associations with clinical outcomes, adjusting for potential confounders including socioeconomic factors, medical conditions, and potassium levels. RESULTS: The one-year prevalence of hyperkalemia (defined as serum potassium, K+ >5.0 mmol/L) was 17.8 %. RAASI were down-titrated in 16.1 % of these 13,673 patients with K+ levels. Factors linked to a higher likelihood of reducing/discontinuing RAASI after developing hyperkalemia included older age, impaired kidney function, higher potassium levels, and previous hospitalizations. Dose reduction/discontinuation of RAASI after developing hyperkalemia was associated with an increased risk of hospitalization (adjusted hazard ratio [HR] 1.16, 95 % confidence interval [CI] 1.10-1.21) and with increased mortality (HR 1.60, 95 % CI 1.56-1.84). CONCLUSION: In this large, observational study, hyperkalemia was linked to a greater likelihood of discontinuing RAASIs. Down-titration of RAASI was independently associated with unfavorable clinical outcomes such as hospitalization and specially mortality. Although the observational nature of the study, these findings underscore the importance of preventing circumstances that may lead to RAASI down-titration, such as hyperkalemia, as well as preventing hospitalizations and mortality, to ensure RAASI benefits.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bioheart Group, Cardiovascular, Respiratory and Systemic Diseases and cellular aging Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain; Community Heart Failure Program,…
- Department of Cardiology, Hospital del Mar, Barcelona, Spain; Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
- Healthcare Information and Knowledge Unit, Institut Català de la Salut (ICS), Barcelona, Spain.
- Servei Català de la Salut (CatSalut), Barcelona, Spain; Digitalization for the Sustainability of the Healthcare System (DS3), IDIBELL, Barcelona, Spain.
- Bioheart Group, Cardiovascular, Respiratory and Systemic Diseases and cellular aging Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.
Förderung
- CSL Vifor
Zitieren
APA
Jiménez-Marrero, S., Cainzos-Achirica, M., Monterde, D., Vela, E., Enjuanes, C., Yun, S., Garay, A., Moliner, P., Corbella, M., Jovells-Vaqué, S., Alcoberro, L., Pons-Riverola, A., Ramos-Polo, R., Morillas, H., Gómez-Hospital, J. A., & Comin-Colet, J. (2024). Serum potassium abnormalities, renin-angiotensin-aldosterone system inhibitor discontinuation, and clinical outcomes in patients with chronic cardiovascular, metabolic, and renal conditions: A population-based analysis. European Journal of Internal Medicine. https://doi.org/10.1016/j.ejim.2024.03.021
Vancouver
Jiménez-Marrero S, Cainzos-Achirica M, Monterde D, Vela E, Enjuanes C, Yun S, et al. Serum potassium abnormalities, renin-angiotensin-aldosterone system inhibitor discontinuation, and clinical outcomes in patients with chronic cardiovascular, metabolic, and renal conditions: A population-based analysis. European Journal of Internal Medicine. 2024. doi:10.1016/j.ejim.2024.03.021
BibTeX
@article{JimnezMarrero2024,
author = {Jiménez-Marrero, Santiago and Cainzos-Achirica, Miguel and Monterde, David and Vela, Emili and Enjuanes, Cristina and Yun, Sergi and Garay, Alberto and Moliner, Pedro and Corbella, Miriam and Jovells-Vaqué, Sílvia and Alcoberro, Lídia and Pons-Riverola, Alexandra and Ramos-Polo, Raul and Morillas, Herminio and Gómez-Hospital, Joan Antoni and Comin-Colet, Josep},
title = {Serum potassium abnormalities, renin-angiotensin-aldosterone system inhibitor discontinuation, and clinical outcomes in patients with chronic cardiovascular, metabolic, and renal conditions: A population-based analysis},
journal = {European Journal of Internal Medicine},
year = {2024},
doi = {10.1016/j.ejim.2024.03.021}
}
EUVIMED